Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Predictive Factors and Magnitude of Response to Omalizumab and Mepolizumab in Allergic and Eosinophilic Severe Asthma: a Pragmatic Multicenter Trial in Belgium.

NCT03476109 is registered in ClinicalTrials.gov with Cliniques universitaires Saint-Luc- Université Catholique de Louvain as lead sponsor.

NCT NCT03476109
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03476109 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Predictive Factors and Magnitude of Response to Omalizumab and Mepolizumab in Allergic and Eosinophilic Severe Asthma: a Pragmatic Multicenter Trial in Belgium.
Lead sponsor
Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Phase
Phase 4
Overall status
Unknown status
Start date
May 10, 2019
Completion date
December 31, 2024
Enrollment
100 (estimated)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

severe asthma